73%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
73%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
73%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
73%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Simulations Plus Inc
Cerrado
SectorSanidad
19.74 0.92
Resumen
Variación precio
24h
Mínimo
19.2
Máximo
19.9
Ingresos | 67M -681K |
|---|---|
Ventas | -2.9M 17M |
P/B Media del Sector | 48.528 77.671 |
BPA | -0.034 |
Rentabilidad por dividendo | 0.48 |
Margen de beneficios | -3.9 |
Empleados | 212 |
EBITDA | 327K 5.3M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +4.86% upside |
Rentabilidad por dividendo Media del Sector | 0.48% 2.35% |
|---|
Capitalización Mercado | 49M 394M |
|---|---|
Apertura anterior | 18.82 |
Cierre anterior | 19.74 |
Simulations Plus Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Simulations Plus Inc previsión
Precio Objetivo
By TipRanks
4.86% repunte
Estimación a 12 Meses
Media 20.5 USD 4.86%
Máximo 25 USD
Mínimo 16 USD
De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Live chat